-
Early-onset colorectal cancer is increasing, what are the characteristics?
Time of Update: 2022-03-07
2. Strengthen precise screening of high-risk groups and general population screening About 16% of patients with early-onset colorectal cancer have an associated genetic syndrome, and another 25% have a family history of CRC, according to current screening guidelines in the United States and the United Kingdom , they can be screened early .
-
【News】Tumor can be eradicated in 5 minutes!
Time of Update: 2022-03-07
They recently published the experimental results in Nano Research, titled "NIR-II photothermal therapy for effective tumor eradication enhanced by heterogeneous nanorods with dual catalytic activities" .
The therapy involves injecting nanomaterials, especially gold nanorods, into the tumor and then activating it with a near-infrared second-region laser that humans cannot perceive .
-
2022 ASCO GU Professor Zeng Hao commented: PROpel-Olapali targets the entire front-line population of mCRPC
Time of Update: 2022-03-06
A phase II clinical study (NCT01972217, study08) of mCRPC patients previously treated with docetaxel and not selected for homologous recombination repair (HRR) status showed: olaparib combined with abiraterone versus placebo Compared with abiraterone, patients' radiographic progression-free survival (rPFS) was improved .
-
Conquering "silent killers" in gynecological tumors, are we still far?
Time of Update: 2022-03-06
It is believed that with the improvement of the availability of new drugs, it will help more ovarian cancer patients benefit from innovative treatments, delay recurrence, achieve survival benefits, improve quality of life, reduce the economic burden on patients' families, and better protect the people.
-
Received five FDA qualifications in one year!
Time of Update: 2022-03-06
S. Food and Drug Administration (FDA) has granted its placental hematopoietic stem cell-derived natural killer (NK) Orphan drug designation for cell therapy CYNK-101 for the treatment of gastric or gastroesophageal junction (G/GEJ) cancers .
-
Sequential CAR-T therapy with different targets brings new hope for childhood Burkitt lymphoma
Time of Update: 2022-03-06
CD19-targeted CAR-T cell therapy has been shown to achieve 6-month complete remission (CR) rates of 29%-41% in adult R/RB-cell lymphoma patients .
In addition, sequential murine CD19 (mCD19)-human CD22 (hCD22)-hCD20-hCD19 CAR-T cell infusion was evaluated in pediatric patients with R/R Burkitt lymphoma and reported early responses, In this study, Prof.
-
Express CRISPR gene editing + natural killer cells, Intellia cooperates to develop anti-cancer therapy
Time of Update: 2022-03-06
It uses a modular genome editing platform to create in vivo and in vitro therapeutic pathways covering multiple indications, with a focus on CRISPR/Cas9-based drug discovery and development of innovative cell therapies for various cancers and autoimmune diseases .
-
Betting on NK cell therapy, Intellia and ONK reached a cooperation of more than 900 million US dollars to develop CRISPR gene editing cancer cell therapy
Time of Update: 2022-03-06
Written | Edited by Wang Cong | Typeset by Wang Duoyu | Shui Chengwen Recently, Intellia Therapeutics, a CRISPR gene editing company founded by Nobel Prize winner Jennifer Doudna, is trading like cra
-
Express treatment of a wide range of tumor types, Ambow Bio's CD70-targeted ADC enters the clinic
Time of Update: 2022-03-06
▎WuXi AppTec Content Team Editor On February 15, 2022, Ambrx Biopharma announced that its IND application for the antibody-drug conjugate (ADC) ARX305 has been approved by the US FDA .
-
Professor Cao Lejie: A new figure!
Time of Update: 2022-03-06
The data are eye-catching, the GEMSTONE-302 study confirms the significant efficacy and benefit of sugalimumab cancer: carboplatin + pemetrexed; squamous cell carcinoma: carboplatin + paclitaxel), compared with placebo plus chemotherapy, in patients with stage IV NSCLC without first-line treatment .
-
Gracell Announces First-in-Human Clinical Trial of Its Dual-Target FasTCAR-T Cell Therapy GC012F for B-Cell Non-Hodgkin Lymphoma Completes First Patient Dosing
Time of Update: 2022-03-06
S. ROOTO, recently, Gracell Biotechnology Group (NASDAQ: GRCL; referred to as "Gracell" or the "Company"), a global clinical-stage company dedicated to the development of highly effective and cost-effective cell therapies for cancer treatment The biopharmaceutical company announced today that it has launched a new clinical trial evaluating the company's core candidate BCMA/CD19 dual-target autologous CAR-T cell therapy GC012F for the treatment of B-cell non-Hodgkin's lymphoma (B-NHL).
-
The third-generation EGFR inhibitor in the targeted therapy series for non-small cell lung cancer (NSCLC) (1)
Time of Update: 2022-03-06
In the CTONG 0901 study, 256 patients with advanced non-small cell lung cancer with EGFR exon 19 or 21 mutations were randomized to receive erlotinib or gefitinib and compared PFS and OS .
-
【PNAS】New Discovery——Breakthrough the Defense of Pancreatic Tumors!
Time of Update: 2022-03-06
Recent studies have identified an immune-inactivating pathway that provides a promising new treatment for pancreatic, breast and colorectal cancers .
-
Professor Zhao Hui from Shanghai Sixth Hospital: Bone pain is an important signal for tumors, and explore the future of healthy aging of bone metastasis and chronic disease
Time of Update: 2022-03-06
In this interview, Professor Zhao Hui, Chief Physician of the Department of Medical Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, will share the common problems of metastatic bone tumors in cancer patients and related bone health management, as well as the future trends of tumor prevention and treatment innovation.
-
NEJM again | KEYNOTE-522 study's fourth interim analysis results announced, pembrolizumab may open up a new situation in early TNBC treatment
Time of Update: 2022-03-06
Foreword On February 10, 2022, NEJM published the results of the fourth interim analysis of KEYNOTE-522, a Phase III clinical trial of pembrolizumab in the neoadjuvant treatment of early-stage triple-negative breast cancer (TNBC), reporting one of the primary endpoints.
-
Express Arvinas Announces Detailed Results of Androgen Receptor PROTAC Protein Degrader (with PPT)
Time of Update: 2022-03-06
Trial results show that bavdegalutamide exhibits potent anticancer activity in the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with AR T878X/H875Y (T878X=T878A or T878S) mutations .
-
Suffering from two types of cancer, how to choose a safe and effective treatment?
Time of Update: 2022-03-06
The disadvantage is that patients suffer; in addition, due to the high heterogeneity of tumors, the gene mutation profiles of different parts may be different, and there may be certain errors in the use of genetic test results to guide subsequent treatment .
-
【Explanation】Professor Shen Yijun: 2022 ASCO GU Blockbuster Research First Look
Time of Update: 2022-03-06
BAYOU is a randomized, phase II clinical study that included 154 patients with advanced first-line UC who were intolerant to platinum therapy and randomized to receive Durvalumab + olaparib (D+O group, n = 78) and Durvalumab + placebo (D+ Group P, n = 76) treatment, the primary endpoint was median PFS in the IIT population .
-
Stage IV Colon Cancer with Multiple Metastases - Bevacizumab Combined with Chemotherapy Leads to 20-Month PFS
Time of Update: 2022-03-06
*Read only for medical professionals Reference Bevacizumab in combination with chemotherapy resulted in up to 20 months PFS in patients with stage IV colon cancer with multiple systemic metastases .
-
Ponatinib plus FLAG-IDA regimen in blast-stage chronic myeloid leukemia (MATCHPOINT): results of a single-arm, multicenter, phase I/II trial
Time of Update: 2022-03-06
Therefore, Mhairi Copland et al designed the MATCHPOINT study to determine the tolerability and optimal dose of ponatinib in combination with the FLAG-IDA regimen in patients with CML-BP .
